PMID- 38189591
OWN - NLM
STAT- MEDLINE
DCOM- 20240219
LR  - 20240219
IS  - 1460-2377 (Electronic)
IS  - 0953-8178 (Print)
IS  - 0953-8178 (Linking)
VI  - 36
IP  - 2
DP  - 2024 Feb 14
TI  - Trends in cell medicine: from autologous cells to allogeneic universal-use cells 
      for adoptive T-cell therapies.
PG  - 65-73
LID - 10.1093/intimm/dxad051 [doi]
AB  - In currently ongoing adoptive T-cell therapies, T cells collected from patients 
      are given back to them after ex vivo activation and expansion. In some cases, T 
      cells are transduced with chimeric antigen receptor (CAR) or T-cell receptor 
      (TCR) genes during the ex vivo culture period in order to endow T cells with the 
      desired antigen specificity. Although such strategies are effective in some types 
      of cancer, there remain issues to be solved: (i) the limited number of cells, 
      (ii) it is time-consuming, (iii) it is costly, and (iv) the quality can be 
      unstable. Points (ii) and (iv) can be solved by preparing allogeneic T cells and 
      cryopreserving them in advance and methods are being developed using healthy 
      donor-derived T cells or pluripotent stem cells as materials. Whereas it is 
      difficult to solve (i) and (iii) in the former case, all the issues can be 
      cleared in the latter case. However, in either case, a new problem arises: 
      rejection by the patient's immune system. Deletion of human leukocyte antigen 
      (HLA) avoids rejection by recipient T cells, but causes rejection by NK cells, 
      which can recognize loss of HLA class I. Various countermeasures have been 
      developed, but no definitive solution is yet available. Therefore, further 
      research and development are necessary.
CI  - (c) The Author(s) 2024. Published by Oxford University Press on behalf of The 
      Japanese Society for Immunology.
FAU - Kawamoto, Hiroshi
AU  - Kawamoto H
AD  - Laboratory of Immunology, Institute for Life and Medical Sciences, Kyoto 
      University, Kyoto 606-8507, Japan.
AD  - Laboratory of Regenerative Immunology, International Center for Cell and Gene 
      Therapy, Fujita Health University, Toyoake 470-1192, Japan.
FAU - Masuda, Kyoko
AU  - Masuda K
AD  - Laboratory of Immunology, Institute for Life and Medical Sciences, Kyoto 
      University, Kyoto 606-8507, Japan.
LA  - eng
GR  - JP19am0401004/AMED/
PT  - Journal Article
PL  - England
TA  - Int Immunol
JT  - International immunology
JID - 8916182
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - T-Lymphocytes
MH  - Killer Cells, Natural
MH  - *Neoplasms
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Receptors, Antigen, T-Cell
PMC - PMC10872703
OTO - NOTNLM
OT  - CAR-T cell therapy
OT  - HLA
OT  - NK cells
OT  - adoptive cell therapy
OT  - iPS cells
EDAT- 2024/01/08 12:43
MHDA- 2024/02/19 06:42
PMCR- 2024/01/08
CRDT- 2024/01/08 09:59
PHST- 2023/09/07 00:00 [received]
PHST- 2024/01/04 00:00 [accepted]
PHST- 2024/02/19 06:42 [medline]
PHST- 2024/01/08 12:43 [pubmed]
PHST- 2024/01/08 09:59 [entrez]
PHST- 2024/01/08 00:00 [pmc-release]
AID - 7512763 [pii]
AID - dxad051 [pii]
AID - 10.1093/intimm/dxad051 [doi]
PST - ppublish
SO  - Int Immunol. 2024 Feb 14;36(2):65-73. doi: 10.1093/intimm/dxad051.